Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did the first time round thanks. Just couldn’t believe you thought that corroborated your “conclusions”. Thought you may have posted the wrong link. But apparently that sentence somehow made you think it did. It didn’t.
We will all anxiously await your interpretation. Hopefully it’s a great one!!!! Again. Maybe the street will take notice this time. LMBO. Fingers crossed!!!
LMBO. Is this the quote you were talking about?
“early signals of efficacy in improving blood counts were observed.”
Off to the races we go with that one. Pretty detailed and pretty much exactly what you took from it. Great job. Keep it up. LMBO. Can’t wait for your result analysis from the next cohort in about another year. Fingers crossed!!!
It’s safe? AMAZING!!! Two years to enrol 3 patients and we know it’s safe. We should have gone up at least a dime on that one. Maybe another couple mil in bonuses for the twins. Sky’s the limit. Maybe in another year, we will get some safety data on the next cohort of 6. Fingers crossed!!!
All of their data has been earth shattering right? It’s why we get a huge gain any time they announce it. But maybe you’re in the controller camp too. Waiting until giant partnership to be announced in plx Immune before they let go of their 10 year hold on this garbage of a stock. Jokes. And trying to make the results seem better than they are is that as well. Whole market knows it. Like I said many times, we’d get a big jump if we got rid of the goons running this thing.
But like always, be good with them. It’s understandable why you are.
No controller necessary. We got the twins to take care of that. Little premature on the wages and free shares. There has never been an argument as to why the goons should remain. Not a single one. Any attempt would be shot down easily. But there’s a ton of argument why they have to go. Why else does our price drop every single time news is released. Nobody believes them at all.
Now we have some claiming dilution will bring about another great buying opportunity. Absolute jokes. Can someone say koolaid. Partnership is obviously out of the question with their big upcoming breakfast. Wouldn’t be necessary if something was imminent on that front.
But could something of significance happen before that in the way of some government agreement or funding for ARS. Slight chance imo. Why else would they be planning such an event. For their sake I hope so. Or they’ll be laughed at like the couple of idiots they truly are if nothing happens beforehand. But I’m not holding my breath.
Pancakes anyone? Flipped often. Never once, unlike some, have I told anyone to sell, buy, nada. And I certainly wouldn’t tell someone it’s going lower and hold on to my shares while they do. That would be idiotic. Flippity flippity flip flop
Imagine where the price would be if it wasn’t “the year of the shareholder”. Kaki himself doesn’t bet on Pluristem, so why does he advise others to not bet against them. And he’s “in the know”. Pretty sad, but not surmising from an accountant made CEO. Laughable
No problem as long as you leave your “conclusions” to the pros. The share price speaks volumes about how correct your “conclusions” are. Even sending the principal investigator on the world tour couldn’t help out. Why? We have the worst management ever and NOBODY believes them. But like always, be happy with them. LMBO.
And remember, you’re the one who brought me into this conversation like I somehow agreed with you. I didn’t and don’t.
About the same likelihood of them being anywhere close to being half enrolled. Pretty much ZERO. LMBO
Theoretically they could though. Get my point. And you’re right, not wasting too much time reading your posts. Way too many holes.
They could enrol entirely in the first day right. So I was agreeing with your point that it COULD. Seems to me you’re getting a little desperate too. Big guns are out in full force...anything to try and help share price for the dilution that’s coming most likely. Reading way too much between the lines as to what’s actually been seen from a whopping 3 patients. Again, laughable.
Well I guess your hoping for 2 crappy management teams to pay off for you then. Again, how they going to fund this stuff? By eoy could be down to $10 mil, of not more.
You take that out of context. Of course they could announce results. But I have always said it’s not going to happen. So DON’T try and throw me in on your extremely optimistic thoughts. They are a long way away I’m sure. They want to announce the first 3 in HCT, Im sure they’d announce progress in CLI if it was happening. They’re desperate you know.
bounces around on the neutrophils as well. They stated conclusions right there, just nada on efficacy.
Wow seems to me you were burned by management before. You’d think you would have learned your lesson. Sound a lot like our beloved twins, only looking out for themselves.
But with the latest news it seems like our twins are grasping at anything. Releasing results of 3 patients out of 24 patient trial that’s been going on for almost 2 years. Big meeting coming up. Still hanging on to hopes a show will finally pay off. But let’s do them incognito now as to not piss off the shareholders more by putting them on the events page.
How are they even going to keep these trials funded? Any thoughts on that one?
Why hasn’t hip fracture even started although was supposed to in June?
These guys are laughing stocks of the biotech world. But they’re better than Wotton. LMBO!!!
Where did I say that? There’s no doubt in my mind that they aren’t even close to the halfway mark. I would truly be surprised if they’ve enrolled 40 patients. And even that is highly optimistic. There’s a reason they don’t announce enrolment numbers at updates, and it’s no wonder. They take years to enrol anything. Take HCT as a case in point. Almost 2 years to get through 3 patients. Wow!!!
Why didn’t they come to the same “conclusions” you did? Just look at patient 1. Their number was bouncing around significantly before treatment. Bouncing around post treatment as well. They left out most of the pretreatment data on the other two graphs, so we don’t get to see that in those 2 for some reason. Some gains, some losses. Not saying there isn’t improvement, but pretty hard to pinpoint with any consistency. Wonder if that’s why they left out efficacy on their own conclusions. Market and their own pros certainly didn’t think much.
And besides, we should see the other cohorts in about 4 more years. Fingers crossed!!!
Nah. Hoping the fast track in Japan results will be better with significance. Maybe the cultural difference there will allow for better results. Maybe they will put the 2 donor cohort in the trial design. Maybe even...wait for it...a 3 donor cohort. We only need to enrol 75, so with Sosei deal making great progress, could be announced any year now like I said. Then conditional approval!!! May even happen this year!!!
I wouldn’t be surprised to just see Japan skip the trials altogether and just give full approval, now that results are in!!! With World Courier ready to handle logistics of our Japanese sales, we’re all set. Fingers crossed!!!
I particularly like the upgrade of facilities in Japan. Maybe that was done specifically for when our fast tracked phase 2 IC trial starts any year now in Japan!!! Go Pluristem!!!
That is a much better link than whalewisdom that I was looking at. Search that page for pretty much any biotech. Even Cytori was there. Again, a positive yes. Just not as big a deal considering the amount of cash they have and the number of positions. From what I saw from Whalewisdom we were about their 2432 biggest position.
Take a look at January 2017 presentation. These are all the 12 month goals. Here we are almost 2 years later, and how many were achieved. But that’s what you get with inexperience. You get what you pay for, even when you pay way too much for it. Especially looking the business development goals near the bottom. But yes, that’s progress. For the book, Progress For Dummies.
Data readout dose selection studies ARS- H1/2017
FAIL...Contract with U.S. government for ARS – H2/2017
FAIL...Initiation of pivotal study ARS NHP- H2/2017
FAIL...Data readout phase I open label HCT- H2/2017
Preclinical data Fukushima- H1/2017
FAIL...Preclinical data NYBC- H1/2017
Initiate advanced pivotal (pre-marketing) clinical trials:
Critical Limb Ischemia (CLI) – U.S., EU, Japan
Hip fracture – U.S., EU
FAIL...ARS
Clinical data readout
Intermittent Claudication (IC)
ARS- U.S. NIH dose selection trial
FAIL...Incomplete engraftment of hematopoietic cell transplantation – open label
Business development
FAIL...Japan- close the Sosei deal and form a JV
35
FAIL...U.S. – negotiating contract with government for ARS
FAIL...China- licensing/JV with Chinese partner
http://www.pluristem.com/wp-content/uploads/2016/04/Pluristem-January-2017.pdf
Renaissance throws cash at many small biotechs. First 5 I looked at have some cash in there. BCLI, MESO, ATHX, ADVM, ADXS. And that’s just top holders in each. Most likely have a stake in most similar biotechs. Must be nice to have almost a $100 billion to invest with.
Have a look at any you want and you will most likely see them there. They throw at most hoping some stick. Better having them there than not, but really means little imo.
Funny the 4 main points are still valid
1 “Pluristem has a long history of ethically questionable reporting to investors”
Still have yet to become transparent in any way whatsoever. No CC’s, no updates of relevance, milestones have disappeared altogether. If anything, it’s much worse.
2 “Stock price jumps ostensibly on analysis published by a discredited bucket shop”
Have a look at the pump from Oct last year and where we are since that raise.
3 “Heavy dilution is imminent and could have a significant negative effect on the share price.”
Three raises since then and an ongoing ATM. The most critical time with regards to financing is imminent. Have to figure out something soon or will get much worse quickly.
4 “Top executives have zero educational and professional experience in the biotech field”
The number one relevant point of them all. If anything, they have promoted inexperienced people and hired even more with little to no experience.
I truly think a change in leadership with a high level executive from a big pharmaceutical would double our price instantly. By looking at the pedigree of our top executives, has to make you wonder the experience of all the other employees. Wonder how many were picked from Elbit. Cmon over here. We’ll make a new title, just for you. Do good and do what we say, and who knows, you could reach executive status in a crazy short period of time.
Zami’s recent golden parachute for change of ownership, is also a positive imo. Maybe some changes are expected or have at least been brought up. There were a surprising amount of yes votes for them all at the last AGM. Wonder if many of these yes votes put a timeframe on something to vote the way they did. Their last chance to make the year of the shareholder actually come true for once. Otherwise... We can only hope something comes soon. Yesterday would barely be soon enough.
Yes Ark to save all the drowning investors. Quite fitting. I do wonder if they’re the ones responsible for us remaining at these levels and not going sub $1. Doubt they’re acquiring from the ATM. At these prices, not taking much for them to get a sizeable position. And I must say, they are intriguing if you look at their philosophy.
Their performance is quite extraordinary as well. $274 mil at the start of 2017, and as of Sept 30/18, $3.3 billion. They’ve got to be doing something right to raise and grow that amount in such a short period of time.
Phase 1 and they probably still have a better shot of getting product to market first. Our CLI will take years sadly. But that’s what you get when you look at our about page.
Regardless you miss my point of how each and every biotech company has experience but ours. Shameful how they surrounded themselves with this.
Highly unlikely unfortunately.
Go take a look at their about page. See what’s different between us and them. It’s night and day.
http://sigilon.com/about-us/
Here’s my 4 reasons for why I’m still willing to take a gamble on this thing.
1 ARS. While I find it odd that this has not moved anywhere close to where I thought it would be now, a contract or at the very least, a funded pivotal trial of perhaps $50 mil is still a possibility. Don’t think the interest is there in the least imo, even at the prices I mention. But you never know.
2 A buyout. Would be fine if someone offered $500 mil to a $1 billion. Would be a substantial gain and would at least allow everyone who has been invested here, to make a pretty big gain, depending on entry points. Or a hostile attempt. Would have no problem with that whatsoever.
3 Ark or someone like that. I find Ark’s recent purchases interesting. They have a unique strategy, a fair size fund, and for some reason has chosen us. They’re strategy is “disruptive technilogies”, so they seem to see something at least. I would like to see them continue to add, and may help bring interest from someone. Be it a potential partner, other funds, something. Would like them to take a more active role somehow, if they continue to add.
4 Manufacturing. It’s possible this industry is not able to produce high quality, commercial scale cells. This is my biggest hope. I don’t think the TF collaboration is to mass produce anything for Pluristem in regards to stockpiling. It may be to see if our technology could be expanded to commercial scale.
A 75L bioreactor is NOT the solution. Twins have been trying to increase size of bioreactor for many years, and we have heard nothing. Still sitting at 75L as far as I know. But if Thermo can figure it out, and others haven’t yet, could be a very lucrative venture.
But truly no matter what, the likelihood of things changing, remain bleak unless we get industry veterans running this company ASAP. Could you imagine getting a senior person from Teva, J&J, Novartis, any big one. And then replacement of other dead wood, all filled with experienced personnel.
Twins and everyone would still stand to make a fortune with the hundreds of thousands to millions of free shares they unfortunately received over all these years, while shareholder get squat. You would think after all these years of not being able to get this stock moving anywhere, they themselves would want this.
Someone had just posted recently that I was wrong about the funding Pluristem received. I wasn’t. They even quoted Kaki’s misleading statement of how much cash they have, which didn’t take off payables. Or thought the $8 mil “additional resources” was cash in our hands, when it’s all for the other parties involved.
That’s what happens when you listen to the inexperienced leaders we have, and always points to who they are looking out for no matter how dire things are financially at the moment, themselves. The newest twin is a dang accountant, and they know full well of the situation they are in, but still leave out key parts to help not make the situation look as dire as it is. Just another reason for these guys not to be trusted at all, and everyone knows this. Hence our garbage price. Did they take a pay cut I wonder now that we have started to enter cash saving mode? What is the cost cutting contingency plan and how close are they to implementing it. Will they forego their pay if that happens? They’re the ones who would have brought us to this desperate point, so you think they would. Time will tell.
And all of this brings me back to Ark. if they could get an ever increasing position in this thing, maybe they will get some pull to make this absolutely necessary cleaning of house, happen. They’ve amassed a fair size position incognito. Keep it going and maybe they could get a bigger stake where their votes matter.
So these are the reasons I will continue to gamble a small amount in this company. CLI is years away, Hip replacement is a joke imo, considering it’s the only one wanting this indication, as others don’t think it’s viable or even that big imo. Every other indication other than this, has companies entering at a growing pace. I wish they had gone solely after a MS, ALS, or something else that has a dire need, that would be enrolled quickly. Thought CLI would possibly be that, but hasn’t been so far at least. But we are where we are and will have to wait.
And the one biggest factor this company is where it’s at right now, is the absolute lack of any communication to shareholders. I truly have never seen anything like this with any company. Not even close. I truly don’t understand how a company that has had this sort of potential, has stated so silent for their entire history. Maybe because they don’t want the real shape of this company to come to light. Maybe the same reason they NEVER hire industry veterans. Don’t want anyone with knowledge to see.
So please for the sake of everyone long in this stock, step down and let someone, one not 2, take over. Two of them have continued to be unable to deliver, so let one capable person take over and have a shot, before it truly is too late. You owe that to shareholders to say the least.
So call me a basher all you like. All I have ever wanted is for this company to succeed. More than most probably. But I will continue to point out their many gaffs until this goes under, which is what I think will happen if twins remain, or someone else leads us in the right direction. How anyone is good with these guys is amazing, or a conflict for their agenda. There’s NO other logical explanation.
You’re right I’m always up for discussion. As for needing something very very clear, you yourself weren’t even very clear on what you were stating. Hence the reach out to Karine.
I have pointed out many things that validate my concerns on the topic of management and how they run this company. There are a ton of proven changes in directions, possibility of manufacturing gaff, never once hiring an experienced big pharma executive to their upper management or board, as pretty much every other biotech company has done. The missed milestones, the misleading updates, the keep you guessing press releases worded to confuse, zero cc’s, zero enrolment updates, large, and I mean large, premature bonuses, zero transparency, zero real update with ARS or potential stockpiling agreement. (Kind it reminds me of the invading caravan about to attack the border) Three patients fully through study period in about 20 months with only three more enrolled. Only got to get to 34 right. Five and a half year IC trial, no mention of NYBC, lille to no data on Fukushima release. Biggest one of all, our great share price
These are just off the top of my head. I’m sure if I looked only at their presentations over the years, it would easily double. So you still being good must be a result of wanting really really really really really good points that show you this, before you think otherwise.
And yes my views may seem or better yet, actually be slanted. I’ve been in for more than 8 years (probably 10+ now) and our price is approaching our all time lows at least post split. I would consider it being a realist. And the reason a poster’s opinion of the trial result brings about little at best, change in my opinion about this company
Well I’m sorry I don’t think they would wait before starting any sort of treatment. Heck these people could only eek out between 1 and 10 minutes at absolute maximum, of walking. Would be nothing but cruel to make them wait until they can get to the trial. Especially considering the standard of care produces such stellar results at least when it comes to MWD.
Of course there are no quantitative facts when it comes to many of the points I bring up. But I have always provided plenty of evidence to assist in my personal conclusions. At least I don’t try to bring up a claim of supervised training to back up my point, and stick to it no matter how silly that seems imo.
Thanks for the reply Midas. It has been an agonizing journey, and yes the forever tomorrow, next month, next year, next show was old after the first year. I think we all know what a joke those comments are, along with the fictitious dots to Lonza, Celgene, and the latest and greatest Novo.
At least I think we will know soon enough if we will survive or fail. I’ve been in this way too long and just want it to end, one way or another. Would love nothing more than to see a miracle, but I truly don’t see it happening. We will see though and really would like to see the long longs rewarded for their patience.
It is a pretty good board here too Mikems. I just wish others would chime in with their beliefs on subject matters as well. Today’s topic of the trial results is a case in point. Maybe some others could bring about their own thoughts on the subject. At least we could get some input others view of the many points Maeve.
Maybe some just don’t want to go against the one who assists in bringing positive outlook for this company. Maybe some don’t want to be attacked by myself and others, I don’t know. I don’t attack unless provoked by others trying to discredit me with baseless, useless posts like tutes and analysts, or scientists and no bad news. Hardly an argument imo. Especially when proven wrong time and time again with zero ability to admit their flawed conclusions when even proven with actual posts they themselves posted.
I admitted myself my assumption on AFS was wrong on the updated results. I honestly did not see that until Spidey pointed it out. There were none in the treatment arm. I’m just not sure how relevant it was as no p value was given, and Pluristem themselves omitted it from their conclusions. They also harped on the proper dosing aspect taken to justify their CLI study. No mention at all about AFS. So probably not that significant, but a positive nonetheless.
Sorry never saw this post. I never once said supervised training would not be found. Well then if supervised training is the standard of care which I’m sure it is, they all would have been receiving it already upon diagnosis? Or did they wait for fresh, newly diagnosed patients to come through, wait for progression to the acceptable trial criteria, then go through the Pluristem trial?
Or were they already given the supervised training as their standard of care and the NEW supervised training during the trial show such an additional improvement?
I’m not sure how so many can try and spin things any which way to try and validate their points that are easily debunked. Luckily I do a lot of DD so I can easily spot it right in front of my face when it appears, which it has a lot today. Sheesh!!!
Funny I don’t get ANY counters to the things I supposedly “spin”.
But you didn’t answer where the supervised training came from.
Not a problem at all. I do try to find pertinent information to back up my claims. Don’t try to pretend I understand those charts but when the placebo group comes second, it raises eyebrows to the relevance imo. And not even sure anyone can with the limited information that’s on it. Kind of par for the course though.
That’s the trial design sorry. The FDA or EMA and Pluristem agreed upon it. Don’t see how they wouldn’t want 36 month follow up. Even if most amputations occur in the first 6 months. BTW, it would be better if you provide the 6 month amputation claim from some other source than a Pluristem presentation. Not saying it’s not, I don’t know. But we all know how many holes have been found in their presentations.
I’m done on all these topics right now. I think I’ve made my points. We will await your confirmation from Karine. Make sure she does tell you the placebo groups apparent successful numbers as well.
Now where are you getting “supervised training”? Why has nobody then done a clinical trial for supervised training since there’s such a dramatic increase from it? Or why would Pluristem put this as their only measure on the design of the trial, if something as simple as supervised training can reach half of what Pluristem’s treatment can.
I’m sorry. Just not buying it. If it were the case as you suggest, that would be pretty substantial to go from 10 minutes at most (most likely much lower) to 56 minutes...with a substantial incline to boot. Funny how our share price doesn’t believe it either.
I don’t think it’s harsh at all, considering we were told they were able to get that sample size to that low of a number based on the lengthy follow up time.
I know where you got the log representation, the 56 minutes is what I’m talking about. Log is represented in the first slide as well, and the placebo group is in second just below the best cohort. How many improved minutes of walking would you assign the placebo group then with your numbers? That’s all I’m basing my observation on as calculus is not my cup of tea.
My bad it is 2 out of the 6 endpoints that don’t have 36 month follow up. And having that 36 month estimated completion date truly is ridiculous like I was insinuating. How could that have even gotten put in there??? Hmmm. Another great leadership moment most likely.
But yes we could see some sort of result coming in the next 6 months or so. Definetly won’t be on any amputation free results at 36 months. Maybe for foot ulcer, but that doesn’t buy you much when dealing with CLI. Would be too big of a jump off the CLI indication. But I think the true odds of us hearing anything about this trial in the next year is about the same as them making their estimated deadline. If they were progressing at any sort of speed, they would state it guaranteed. Especially how they’re pulling out any stop in an effort to help this pathetic share price.
I’m not sure where you get your numbers from. I see percentages and not entirely sure what the log represents. The placebo group is right up there on the graph as well. I truly don’t see the placebo group coming even close to the improvement you suggest.
To go from 10 minutes to 56 minutes that I think you stated, would be pretty amazing. I just don’t think that’s the case. Especially at a 56% incline. Mine only goes to 40% and that’s a pretty good hill to climb. So I most certainly don’t see many of these elderly patients attaining that, even if healthy.
And if anyone went from even 10 minutes to 56 minutes, that would have been stated in plain English by someone from the company.
When I was searching around trying to find some comparison to distance, I do recall seeing a 6 minute walking test where incline changed. But that test maxed out at 6 mins and a 6% incline.